Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post-PRECISION: What We Thought We Knew Then and What We Think We Know Now

Carlo Patrono, C. Baigent

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The aim of the present review is to analyze how thinking about the cardiovascular safety of nonsteroidal antiinflammatory drugs has evolved during the past two decades, and discuss to what extent the additional information from the Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen study may alter our current mechanistic understanding and/or clinical practice.
Original languageEnglish
Pages (from-to)238-245
Number of pages8
JournalCLINICAL PHARMACOLOGY & THERAPEUTICS
Volume102
DOIs
Publication statusPublished - 2017
Externally publishedYes

Keywords

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal
  • Cardiovascular Diseases
  • Cyclooxygenase 2 Inhibitors
  • Gastrointestinal Diseases
  • Humans
  • Pharmacology
  • Pharmacology (medical)
  • Prospective Studies
  • Randomized Controlled Trials as Topic
  • Risk Factors

Fingerprint

Dive into the research topics of 'Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post-PRECISION: What We Thought We Knew Then and What We Think We Know Now'. Together they form a unique fingerprint.

Cite this